

MIR29A impedes metastatic behaviors in hepatocellular carcinoma via targeting, LOX, LOXL2, and VEGFA

- Supplementary Figure S1.....page s1
- Supplementary Figure S2.....page s2




Figure S1. The profile of *MIR29A* gene alteration in various cancer types. Note that *MIR29A* in HCC presented 1.084% of amplification without the presence of deletion and mutation.




Figure S2. The expression level of *MIR29A* in normal tissue and HCC tumor tissue in male and female. Note that there is no potential gender bias acting on *MIR29A* expression in HCC ($p=0.572$ between male and female HCC tissue). *** $p<0.001$ as compared to normal group.